Central Library, KUET

Your cart is empty.
Khulna University of Engineering & Technology
Central Library

Normal view MARC view ISBD view

Phosphodiesterases and their inhibitors / edited by Spiros Liras and Andrew S. Bell.

Contributor(s): Liras, Spiros [editor.] | Bell, Andrew S [editor.].
Material type: materialTypeLabelBookSeries: Methods and principles in medicinal chemistry: Volume 61.Publisher: Weinheim an der Bergstrasse, Germany : Wiley-VCH, 2014Copyright date: ©2014Description: 1 online resource (238 pages) : illustrations.Content type: text Media type: computer Carrier type: online resourceISBN: 9783527682355; 352768235X; 9783527682348; 3527682341; 3527332197; 9783527332199; 9781306531955; 1306531950; 3527682376; 9783527682379; 3527682368; 9783527682362.Subject(s): Cyclic nucleotide phosphodiesterases | Phosphodiesterases -- Inhibitors | Phosphodiesterases -- Inhibitors -- Therapeutic use | Cyclic nucleotide phosphodiesterases | Nucleotides, Cyclic -- physiology | Phosphodiesterase Inhibitors -- therapeutic use | Phosphoric Diester Hydrolases -- physiology | Phosphoric Diester Hydrolases | MEDICAL -- Physiology | SCIENCE -- Life Sciences -- Human Anatomy & Physiology | Phosphodiesterase Inhibitors -- chemistry | Phosphodiesterase Inhibitors -- therapeutic useGenre/Form: Electronic books.Additional physical formats: Print version:: Phosphodiesterases and their inhibitors.DDC classification: 612.01519 Online resources: Wiley Online Library
Contents:
Phosphodiesterases and Their Inhibitors; Contents; List of Contributors; Preface; A Personal Foreword; 1 Introduction; 2 Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry; 2.1 Introduction; 2.2 The First-Generation Agents; 2.3 PDE5 as a Mechanism and Alternative Indications Beyond MED; 2.4 A Summary of PDE5 Chemotypes Reported Post-2010; 2.5 Second-Generation PDE5 Inhibitors from Pfizer: Pyrazolopyrimidines; 2.6 Second-Generation PDE5 Inhibitors from Pfizer: Pyridopyrazinones; 2.7 Conclusions; References.
3 PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors3.1 Introduction; 3.2 Isoforms, Domain Organization, and Splice Variants; 3.3 Structural Features of the Catalytic Site; 3.4 Regulation of PDE4 Activity; 3.5 Crystal Structure of Regulatory Domains of PDE4; 3.6 UCR2 Interaction and Selectivity; 3.7 Conclusions; References; 4 PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects; 4.1 Introduction; 4.2 Brief Summary of pan-PDE4 Inhibitors; 4.2.1 Rolipram; 4.2.2 Roflumilast; 4.2.3 Cilomilast; 4.2.4 Apremilast.
4.3 PDE4 Strategies to Avoid Gastrointestinal Events4.3.1 Allosteric Modulation; 4.3.2 PDE4D Selectivity; 4.3.3 Pfizer; 4.3.4 Novartis; 4.3.5 Merck-Frosst; 4.3.6 GEBR-7b; 4.3.7 PDE4B Selectivity; 4.3.8 Asahi Kasei; 4.3.9 GlaxoSmithKline; 4.3.10 Pfizer; 4.3.11 Tissue Targeting; 4.3.12 Polypharmacology; 4.3.13 Olanzapine Derivatives; 4.4 Conclusions; References; 5 The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A; 5.1 Enzymology and Protein Structure; 5.2 Papaverine-Related PDE10A Inhibitors; 5.3 MP-10/PF-2545920 Class of Inhibitors.
5.4 PF-2545920/MP-Inspired Inhibitors5.5 PF-2545920/Papaverine/Quinazoline Hybrid Series of Inhibitors; 5.6 PET Ligand Development; 5.7 Summary and Future; References; 6 The State of the Art in Selective PDE2A Inhibitor Design; 6.1 Introduction; 6.2 Selective PDE2A Inhibitors; 6.2.1 Bayer; 6.2.2 Altana AG; 6.2.3 Biotie Therapies; 6.2.4 Boehringer Ingelheim; 6.2.5 Janssen; 6.2.6 Lundbeck; 6.2.7 Merck; 6.2.8 Neuro3d; 6.2.9 Pfizer; 6.3 Methods; 6.4 Conclusions; References; 7 Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery; 7.1 Introduction.
7.2 Subtle Asymmetry of the PDE9 Dimer in the Crystals7.3 The Structure of the PDE9 Catalytic Domain; 7.4 Interaction of Inhibitors with PDE9; 7.5 Implication on Inhibitor Selectivity; References; 8 PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases; 8.1 PDE9A Enzymology and Pharmacology; 8.2 Crystal Structures of PDE9A Inhibitors; 8.3 Medicinal Chemistry Efforts toward Identifying PDE9A Inhibitors for Treating Cognitive Disorders; 8.3.1 Bayer; 8.3.2 Pfizer; 8.3.3 Boehringer Ingelheim; 8.3.4 Sun Yat-Sen University, China; 8.3.5 Envivo Pharmaceuticals.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Includes bibliographical references at the end of each chapters and index.

Print version record.

Phosphodiesterases and Their Inhibitors; Contents; List of Contributors; Preface; A Personal Foreword; 1 Introduction; 2 Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry; 2.1 Introduction; 2.2 The First-Generation Agents; 2.3 PDE5 as a Mechanism and Alternative Indications Beyond MED; 2.4 A Summary of PDE5 Chemotypes Reported Post-2010; 2.5 Second-Generation PDE5 Inhibitors from Pfizer: Pyrazolopyrimidines; 2.6 Second-Generation PDE5 Inhibitors from Pfizer: Pyridopyrazinones; 2.7 Conclusions; References.

3 PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors3.1 Introduction; 3.2 Isoforms, Domain Organization, and Splice Variants; 3.3 Structural Features of the Catalytic Site; 3.4 Regulation of PDE4 Activity; 3.5 Crystal Structure of Regulatory Domains of PDE4; 3.6 UCR2 Interaction and Selectivity; 3.7 Conclusions; References; 4 PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects; 4.1 Introduction; 4.2 Brief Summary of pan-PDE4 Inhibitors; 4.2.1 Rolipram; 4.2.2 Roflumilast; 4.2.3 Cilomilast; 4.2.4 Apremilast.

4.3 PDE4 Strategies to Avoid Gastrointestinal Events4.3.1 Allosteric Modulation; 4.3.2 PDE4D Selectivity; 4.3.3 Pfizer; 4.3.4 Novartis; 4.3.5 Merck-Frosst; 4.3.6 GEBR-7b; 4.3.7 PDE4B Selectivity; 4.3.8 Asahi Kasei; 4.3.9 GlaxoSmithKline; 4.3.10 Pfizer; 4.3.11 Tissue Targeting; 4.3.12 Polypharmacology; 4.3.13 Olanzapine Derivatives; 4.4 Conclusions; References; 5 The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A; 5.1 Enzymology and Protein Structure; 5.2 Papaverine-Related PDE10A Inhibitors; 5.3 MP-10/PF-2545920 Class of Inhibitors.

5.4 PF-2545920/MP-Inspired Inhibitors5.5 PF-2545920/Papaverine/Quinazoline Hybrid Series of Inhibitors; 5.6 PET Ligand Development; 5.7 Summary and Future; References; 6 The State of the Art in Selective PDE2A Inhibitor Design; 6.1 Introduction; 6.2 Selective PDE2A Inhibitors; 6.2.1 Bayer; 6.2.2 Altana AG; 6.2.3 Biotie Therapies; 6.2.4 Boehringer Ingelheim; 6.2.5 Janssen; 6.2.6 Lundbeck; 6.2.7 Merck; 6.2.8 Neuro3d; 6.2.9 Pfizer; 6.3 Methods; 6.4 Conclusions; References; 7 Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery; 7.1 Introduction.

7.2 Subtle Asymmetry of the PDE9 Dimer in the Crystals7.3 The Structure of the PDE9 Catalytic Domain; 7.4 Interaction of Inhibitors with PDE9; 7.5 Implication on Inhibitor Selectivity; References; 8 PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases; 8.1 PDE9A Enzymology and Pharmacology; 8.2 Crystal Structures of PDE9A Inhibitors; 8.3 Medicinal Chemistry Efforts toward Identifying PDE9A Inhibitors for Treating Cognitive Disorders; 8.3.1 Bayer; 8.3.2 Pfizer; 8.3.3 Boehringer Ingelheim; 8.3.4 Sun Yat-Sen University, China; 8.3.5 Envivo Pharmaceuticals.

There are no comments for this item.

Log in to your account to post a comment.

Khulna University of Engineering & Technology
Funded by: HEQEP, UGC, Bangladesh